News & Updates

Show Multimedia Only

Coexposure to bisphenols linked to metabolic diseases

10 Aug 2025

A recent study has observed the association of bisphenol A (BPA) and its substitutes with specific metabolic diseases (MDs).

Coexposure to bisphenols linked to metabolic diseases

10 Aug 2025

Outcomes after sleeve gastrectomy differ across race, ethnicities

09 Aug 2025

Glycaemic outcomes following sleeve gastrectomy (SG) vary by race and ethnicity, with non-Hispanic Black (NHB) participants showing less favourable outcomes, reports a study.

Outcomes after sleeve gastrectomy differ across race, ethnicities

09 Aug 2025

GLP-1RAs may provide migraine relief independent of weight loss

08 Aug 2025 by

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have the potential to reduce the frequency of migraines even in patients who do not lose weight—an effect that may be related to a reduction in intracranial pressure, according to a pilot prospective observational study.

GLP-1RAs may provide migraine relief independent of weight loss

08 Aug 2025

GLP-1 RAs reduce glaucoma risk in patients without diabetes

07 Aug 2025

Patients without diabetes who use GLP-1 receptor agonists (RAs) display a lower risk of primary open-angle glaucoma (POAG) and ocular hypertension than those who use other weight-loss therapies at 3- and 5-year intervals, a study has shown.

GLP-1 RAs reduce glaucoma risk in patients without diabetes

07 Aug 2025

Obesity tied to target organ damage indices

04 Aug 2025

Obesity shows a significant relationship with several indices of asymptomatic cardiac remodelling and vascular atherosclerosis, according to a study. Moreover, this association is mediated by systolic blood pressure (BP).

Obesity tied to target organ damage indices

04 Aug 2025

Weekly fixed-dosed efsitora as good as daily glargine in T2D

04 Aug 2025

For adult patients with type 2 diabetes (T2D) who are naïve to insulin, a once-weekly fixed-dose efsitora regimen is noninferior to once-daily glargine at reducing blood glucose levels, according to the phase III treat-to-target QWINT-1 trial.

Weekly fixed-dosed efsitora as good as daily glargine in T2D

04 Aug 2025

No excess liver cancer risk seen with oral contraceptive use

03 Aug 2025 by

Two large prospective cohorts show no evidence of an association between the use of oral contraceptives and the risk of liver cancer.

No excess liver cancer risk seen with oral contraceptive use

03 Aug 2025

Risk of MACE higher with sulfonylureas vs DPP4is

02 Aug 2025

In the treatment of patients with type 2 diabetes, sulfonylureas pose an increased risk of major adverse cardiovascular events (MACE) compared with dipeptidyl peptidase 4 inhibitors (DPP4is), according to a study.

Risk of MACE higher with sulfonylureas vs DPP4is

02 Aug 2025

Novel system with MDI improves glycaemic control in T2D

31 Jul 2025 by

Older adults with type 2 diabetes (T2D) who are using multiple daily insulin injections (MDI) and the Bigfoot Unity System demonstrate durable glycaemic improvement at 6 months, reports a study.

Novel system with MDI improves glycaemic control in T2D

31 Jul 2025

Thiazolidinedione reduces mortality, adverse events in T2D patients with AKD

31 Jul 2025

Treatment with thiazolidinedione (TZD) results in a significant decrease in mortality, cardiovascular events, and kidney-related adverse events among type 2 diabetes (T2D) patients with acute kidney disease (AKD), a recent study has shown.

Thiazolidinedione reduces mortality, adverse events in T2D patients with AKD

31 Jul 2025

News & Updates

Filter by Specialty:

Specialty:

Coexposure to bisphenols linked to metabolic diseases

Coexposure to bisphenols linked to metabolic diseases

Outcomes after sleeve gastrectomy differ across race, ethnicities

Outcomes after sleeve gastrectomy differ across race, ethnicities

GLP-1RAs may provide migraine relief independent of weight loss

GLP-1RAs may provide migraine relief independent of weight loss

GLP-1 RAs reduce glaucoma risk in patients without diabetes

GLP-1 RAs reduce glaucoma risk in patients without diabetes

Obesity tied to target organ damage indices

Obesity tied to target organ damage indices

Weekly fixed-dosed efsitora as good as daily glargine in T2D

Weekly fixed-dosed efsitora as good as daily glargine in T2D

No excess liver cancer risk seen with oral contraceptive use

No excess liver cancer risk seen with oral contraceptive use

Risk of MACE higher with sulfonylureas vs DPP4is

Risk of MACE higher with sulfonylureas vs DPP4is

Novel system with MDI improves glycaemic control in T2D

Novel system with MDI improves glycaemic control in T2D

Thiazolidinedione reduces mortality, adverse events in T2D patients with AKD

Thiazolidinedione reduces mortality, adverse events in T2D patients with AKD